Andere Sprachen Zealand Pharma A/S

Aktien

A0YJW7

DK0060257814

ZEAL

Biotechnologie

Realtime-Estimate Cboe Europe Andere Börsenplätze 13:04:06 12.12.2024			% 5 Tage	% 1. Jan.
802,25 ^DKK	+4,87 %		+6,48 %	+115,70 %

08:58	DNB nimmt die Coverage von Zealand Pharma mit Buy und Kursziel DKK 1.050 auf - BN	FW
09.12.	Swedbank Robur Småbolagsfond Norden fällt im November um 2,03 Prozent - Netcompany ins Portfolio aufgenommen	FW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity	10.12.
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity	10.12.
Zealand Pharma to participate in the Jefferies London Healthcare Conference	13.11.
Zealand Pharma to participate in the Jefferies London Healthcare Conference	13.11.
Zealand Pharma A/S - Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons	12.11.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	11.11.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	11.11.
Zealand Pharma A/S : Presentation slides (zealand pharma q3 2024 presentation 7 november)	08.11.
Zealand Pharma A/S : Interim Report for Q3 2024	08.11.
Zealand Pharma Announces Financial Results for the First Nine Months of 2024	07.11.
Zealand Pharma Announces Financial Results for the First Nine Months of 2024	07.11.
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	07.11.
Zealand Pharma conference call on November 7 at 2pm CET to Present third quarter 2024 financial results	04.11.
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results	01.11.
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results	01.11.
Actualización de las fuertes variaciones del día: Continental anuncia buenas noticias; temores en Bayer	09.10.
Les actions en mouvement : Continental annonce de bonnes nouvelles ; craintes chez Bayer	09.10.
Zealand Pharma Gets US FDA's Complete Response Letter for Hypoglycemia Drug	09.10.
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism	09.10.
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism	09.10.
Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism	09.10.
Zealand Pharma Gets FDA Complete Response Letter for Hypoglycemia New Drug Application	08.10.
Boehringer Secures Breakthrough Designation for MASH, Fibrosis Treatment	08.10.
Zealand, Boehringer win FDA breakthrough status to treat fatty liver	08.10.
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide	08.10.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zealand Pharma A/S

Aktien

A0YJW7

DK0060257814

ZEAL

Biotechnologie

Andere Sprachen

Filter